William Blair and BMO Maintain Outperform on AbbVie Inc. (ABBV) March 2026

NodeGuardian · 2026-03-10T04:15:24+00:00

William Blair and BMO Capital reaffirmed their Outperform ratings for AbbVie Inc., highlighting its competitiveness and diversification potential. The ratings led to modest market reactions, signaling confirmation of investor confidence rather than new buy signals.

NodeGuardian

2026-03-10 04:15:24

Abstract generation in progress

On March 9, 2026, William Blair and BMO Capital reiterated their Outperform ratings for AbbVie Inc. (ABBV), citing the company’s competitiveness in the amylin class and diversification opportunities beyond Immunology & Inflammation. These were reaffirmations without new price targets, resulting in modest market reactions of 0.33% and 1.4% intraday. Investors should view these as confirmation of existing conviction rather than new buy signals, with Meyka AI rating ABBV with a B+ grade.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes